what does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
Published 6 years ago • 72 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
2:43
pembrolizumab: defining standards of care in urothelial cancer
-
3:51
is pembrolizumab alone sufficient to treat bladder cancer?
-
1:54
two-year follow-up results from keynote-045 study in urothelial carcinoma
-
2:12
real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic uc
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
1:09
keynote-045 – pembrolizumab as second-line treatment in urothelial carcinoma
-
2:29
bladder cancer treatment updates by prof. jones
-
5:40
highlights in bladder cancer from asco gu 2021
-
2:41
firstline pembrolizumab for metastatic urothelial cancer
-
0:58
replacing the current standard of care for urothelial carcinoma
-
31:06
bladder cancer | 2022 oneoncology conference
-
4:04
perioperative treatment strategies for high-risk bladder cancer
-
4:46
changing the standard of care in metastatic bladder cancer
-
3:00
atezolizumab limits disease progression for metastatic urothelial bladder cancer
-
1:03
pout trial: a new standard of care for upper tract urothelial carcinoma
-
2:15
personalized dosing of pembrolizumab has the potential to save $0.8 billion per year
-
2:54
a 6-factor prognostic model for urothelial carcinoma patients receiving atezolizumab
-
2:21
phase 2 pivotal trial of padcev in advanced urothelial cancer
-
1:05
dr. petrylak on combinations with pembrolizumab in urothelial carcinoma